ABCB5 and recessive dystrophic epidermolysis bullosa: Thus, the capacity of ABCB5+ MSCs to dampen IL-1β-driven inflammation [11] (see Figure 4) makes them a promising candidate for disease-modifying treatment strategies in RDEB.